A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis - Related Studies

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

This study is currently recruiting participants.

Study NCT00658567. Last updated on November 17, 2008. Information provided by ACADIA Pharmaceuticals Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Parkinson's Disease Psychosis

2	Additional conditions recognized in this trial
		Parkinson Disease
		Psychotic Disorders

3	More general conditions related to this trial
		Basal Ganglia Diseases
		Brain Diseases
		Central Nervous System Diseases
		Mental Disorders
		Movement Disorders
		Nervous System Diseases
		Neurodegenerative Diseases
		Parkinsonian Disorders
		Schizophrenia and Disorders with Psychotic Features

4	Interventions listed in this trial
		Pimavanserin tartrate (ACP-103)

5	Sponsors listed in this trial
		ACADIA Pharmaceuticals Inc.